Page 150 - CW E-Magazine (18-2-2025)

Top Stories Pharmaceuticals

HEALTH & WELLNESS POISED FOR GROWTH

Vitafoods India showcases cutting-edge products Indian pharma exports to touch $65-bn by 2030 and $350-bn

and emerging nutraceutical trends by 2047: Report

India’s pharma exports are expected Indian Drugs Manufacturers’ Associa- key to API exports growth; India must
The third edition of Vitafoods medium enterprises, India is poised Mr. Sanjaya Mariwala, Executive
India, held in Mumbai from February to not only reclaim its 5,000-year-old Chairman & Managing Director, Omni- to double to $65-bn by 2030 and tion (IDMA), and Pharmexcil. scale efforts to revive and strengthen its
touch $350-bn in value terms by 2047,
API industry while improving energy
5-7, 2025, showcased innovations and legacy in Ayurveda but also emerge as Active Health Technologies, added that moving to top fi ve position globally by “The transition from volume-based supply, waste treatment, and road con-
opportunities driving the Indian nutra- a dominant force in the international with the right synergy between govern- diversifying its product basket, as per to value-led growth is essential for Indian nectivity, he added.
ceuticals market, as well as the future wellness industry,” he said. ment policies and industry initiatives, a report by Bain & Company’s. While pharma to secure its rightful place in
of the business of health and wellness. the sector can unlock immense growth India is the largest supplier of generic the global market. Innovation, includ- Indian Pharmaceutical Alliance’s
‘Thin line between food and medicine’ opportunities, much like India’s suc-
Organised by Informa Markets in Dr. Manoj Nesari, Advisor, Ayurveda, cess in the software industry. “Given drugs globally, accounting for one in ing the shift towards specialty generics, (IPA’s) Secretary General, Mr. Sudarshan
India, the event featured 136 domestic Ministry of AYUSH, Govt. of India, the country’s manufacturing capabili- fi ve generic drugs sold worldwide, the biosimilars, and novel products, will Jain, said India aims to become a $30-
nation ranks 11th in terms of export be the key to India’s pharmaceutical 35 trillion economy by 2047 and to
and 23 international exhibitors, with pointed out that the ayurveda and ties and scientifi c talent, achieving a value. future,” said Mr. Sriram Shrinivasan, achieve that, the pharmaceutical indus-
over 35 expert speakers offering in- nutraceutical sector is experiencing $100-bn market in nutraceuticals is a Partner, Bain & Company. try must excel on all fronts. “It is crucial
sights into industry trends. The event unprecedented growth, with the mar- realistic goal,” he emphasised. As per the report titled, ‘Healing to double down on Indian pharmaceuti-
drew participation from distributors, ket expanding from $3-bn in 2014 to the world: Roadmap for making India With the right focus on quality, cal exports, which currently account for
procurement managers, R&D specia- $18.2-bn by 2020 and currently valued Dedicated Task Force formed a global pharma exports hub’, India regulation, access to global markets, 6 percent of India’s total merchandise
lists, regulatory affairs professionals, at around $24-bn, with a projected tar- Dr. Meenakshi Singh, Chief Scien- can potentially secure a position among talent, and entrepreneurial innovation, exports by value,” he added. The report
and product development experts. get of $200-bn over the next decade. tist, Technology Management Directo- the top fi ve nations in export value by India can rise to be among the top-fi ve stressed that key industry segments like
“The industry is evolving beyond rate, CSIR, noted that the government
Standardisation & research-backed conventional supplements to embrace formed a Task Force under the guid- 2047 by innovating and diversifying pharma exporters globally by 2047, APIs, biosimilars, and generic formula-
its export basket to include specialty he added. IDMA National President, tions were poised to grow signifi cantly
validation need of the hour Ayurvedic Aahar, recognising the ance of the Principal Scientifi c Advisor generics, biosimilars, and innovative Mr. Viranchi Shah, highlighted that going ahead. Besides, collaboration
Addressing at the event, Dr. Sub- immense potential of fl avonoids and in 2021, in collaboration with CSIR and
rata Gupta, Secretary, Ministry of Food alkaloids found in medicinal plants and key industry leaders, so as to address products. The fi ndings in the report India can become one of the leaders between the government and private
were formulated in collaboration with in pharma exports, but needs strate-
sector is crucial for global competitive-
Processing Industries, Govt. of India, everyday foods. The thin line between critical gaps, such as absence of stan- Indian Pharmaceutical Alliance (IPA), gic interventions. Bulk drug parks are ness, it highlighted.
observed that the global nutrition market, food and medicine highlights the signi- dardised codes for export tracking and
valued at $520-bn, is witnessing grow- fi cance of functional ingredients like regulatory clarity. “Moving forward, Alkem Labs announces acquisitions in skincare and medical
ing emphasis on traditional and preven- turmeric, amla, and triphala in promot- we seek stronger collaboration between
tive healthcare. “India’s share, estimated ing holistic well-being.” industry and research institutions to devices segments
around $8-bn, highlights the sector’s generate comprehensive scientifi c data
vast potential, particularly in Ayurveda- Addressing key public health con- that will propel the nutraceutical indus- Alkem Laboratories has announced offer to acquire 100% stake in Bombay diversify its portfolio, enhance market
based nutraceuticals,” he said. cerns, such as iron defi ciency anaemia, try to new heights,” she said. two acquisitions – in the dermato- Ortho Industries Pvt. Ltd., a manu- penetration and strengthen its presence
he added, requires a shift from mere logy and medical device segments – to facturer of orthopaedic implants, for in the growing segments of dermatology
According to Dr. Gupta, with in- supplementation to improving nutri- Mood and mental health – fastest strengthen its position in the domestic around Rs. 147-crore. Mr. B.N. Singh, and cosmetology. Also, our investment
creasing global demand, standardi- ent absorption, a focus highlighted by growing condition market. The company has signed a Alkem Chairman, said, “The acqui- in Bombay Ortho is in line with our
sation, research-backed validation, initiatives like ‘Mission Utkarsh’. Mr. Nishant Chachra, Vice Presi- binding term sheet to acquire 100% sition of Adroit will enable Alkem to strategy for Medtech in India.”
and sustainable cultivation practices dent, Business Development, KSM-66 stake in Adroit Biomed Ltd., a pharma- Caplin Steriles gets USFDA approval for procain-
are critical to strengthening India’s Policy and regulatory support Ashwagandha, a global leader in Ashwa- ceutical company focussed on the skin-
position in the natural wellness sector. Mr. Salman Mehkri, Head, Busi- gandha, noted that mood and mental care segment, for around Rs. 140-crore, amide hydrochloride injection
“Addressing challenges such as quality ness Development, Bio-gen Extracts, health is among the fastest-growing a note from the company said. Adroit Caplin Steriles, a subsidiary of Procainamide hydrochloride injection
planting materials, processing gaps, and stressed the need for Government sup- condition category in supplements. has a differentiated dermatology port- Chennai’s Caplin Point Laboratories, is an antiarrhythmic medicine used to
export compliance can signifi cantly port for accelerating the industry’s “In 2023, sales increased by 6.9% to folio with key brands being Glutone, has been granted fi nal approval from the treat certain arrhythmia (abnormal heart
enhance the sector’s contribution to far- expansion. “Policies such as reducing hit $1.53-bn and is expected to remain SkinFay, Racine and FortiSil. Adroit USFDA for its Abbreviated New Drug rhythm). It restores normal heart rhythm
mers, employment, and foreign exchange the GST on nutraceuticals from 18% in the 6.5% to 7% range through had a revenue of Rs. 53.55-crore in the Application (ANDA) Procainamide by blocking abnormal electrical signals
earnings. By leveraging advanced pro- to 5-12% and introducing PLI-based 2027 driven by increasing consumer fi nancial year ended March 2024. Hydrochloride Injection USP, 1g/10mL in the heart. According to IQVIA (IMS
cessing techniques like gamma irradia- schemes would enhance affordability demand for mental wellness products and 1g/2mL vials, a generic therapeutic Health), the injection had US sales of
tion to improve shelf-life and expand- and accessibility, especially in tier-2 addressing anxiety, stress, and cognitive Separately, Alkem’s subsidiary, equivalent version of the reference listed approximately $20-mn for the 12-month
ing institutional support for small and and tier-3 cities,” he noted. health.” Alkem MedTech, has signed a binding drug, Pronestyl, from Apothecon Inc. period ending December 2024.

150 Chemical Weekly February 18, 2025 Chemical Weekly February 18, 2025 151

Contents Index to Advertisers Index to Products Advertised